Aimmune Therapeutics is a technology company.
Aimmune Therapeutics has raised $80.0M across 1 funding round.
Aimmune Therapeutics has raised $80.0M in total across 1 funding round.
Aimmune Therapeutics has raised $80.0M in total across 1 funding round.
Aimmune Therapeutics's investors include Aisling Capital, Foresite Capital.
Aimmune Therapeutics is not a technology company—it is a biopharmaceutical company focused on developing pharmaceutical treatments for food allergies.[2] The premise of your query contains an inaccuracy that should be clarified before proceeding with the requested analysis.
Aimmune Therapeutics develops and commercializes treatments for potentially life-threatening food allergies using a proprietary approach called Characterized Oral Desensitization ImmunoTherapy (CODIT).[2] The company's lead product, Palforzia, is the first and only FDA-approved treatment to reduce the frequency and severity of allergic reactions to peanuts in children aged 4-17.[4] Beyond peanut allergy, Aimmune is advancing a pipeline of investigational therapies targeting other food allergies, including egg and walnut allergies.[5]
The company addresses a critical unmet medical need: most patients with food allergies currently rely on strict avoidance and emergency epinephrine administration. Aimmune's CODIT approach offers an alternative by desensitizing patients through the oral administration of gradually increasing amounts of allergens, enabling meaningful protection against accidental exposures.[3] The food allergy treatment market stood at USD 1.92 billion in 2024 and is projected to more than double by 2035, driven by rising environmental pollution, changing dietary habits, urbanization, and greater awareness of allergic disorders.[1]
Aimmune Therapeutics was incorporated in 2011 and was originally known as Allergen Research Corporation before changing its name in May 2015.[2] The company was founded in partnership with Food Allergy Research & Education (FARE), the nation's leading nonprofit focused on food allergies, establishing a mission-driven foundation from inception.[5]
The company's CODIT platform is built on extensive independent scientific research demonstrating that most patients with food allergies can become desensitized to allergens through oral immunotherapy with gradually increasing doses.[3] This scientific foundation enabled Aimmune to advance its lead candidate, AR101 (later branded as Palforzia), through clinical development. The PALISADE Phase 3 clinical program successfully tested AR101 for peanut allergy, culminating in FDA approval on January 31, 2020.[6]
Aimmune operates within the broader immunotherapy and allergy treatment sector, riding the wave of advances in precision medicine and immunological understanding. The timing is favorable: rising food allergy prevalence, improved diagnostic capabilities using AI-assisted tools, and growing public awareness have created demand for curative rather than merely palliative solutions.[1]
The company's CODIT approach represents a paradigm shift from avoidance-based management to active desensitization, influencing how the medical community approaches food allergies. As nanoformulations and peptide immunotherapy innovations emerge in the field, Aimmune's standardized platform positions it as a reference model for pharmaceutical-grade oral immunotherapy.[1]
Aimmune's trajectory is shaped by its acquisition by Nestlé Health Science, which transformed it from an independent biopharmaceutical company into a subsidiary of a global nutrition and health conglomerate.[2][4] This ownership structure provides significant advantages: access to Nestlé's distribution networks, manufacturing capabilities, and resources to scale Palforzia globally and accelerate pipeline development.
The company's future hinges on three factors: expanding Palforzia's market penetration in peanut allergy, advancing AR201 and other pipeline candidates through clinical trials, and demonstrating long-term efficacy and safety data that could expand the addressable patient population. As the food allergy treatment market doubles over the next decade, Aimmune's position as the incumbent leader in desensitization therapy—backed by a multinational parent—positions it to capture significant market share in a growing therapeutic category.
Aimmune Therapeutics has raised $80.0M across 1 funding round. Most recently, it raised $80.0M Series B in March 2015.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2015 | $80.0M Series B | Aisling Capital, Foresite Capital |